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Multiple molecular interactions
redundantly contribute to RB‑mediated cell
cycle control
Michael J. Thwaites1,3, Matthew J. Cecchini1,3, Srikanth Talluri1,3, Daniel T. Passos1,3, Jasmyne Carnevale1,3
and Frederick A. Dick1,2,3*

Abstract
Background: The G1-S phase transition is critical to maintaining proliferative control and preventing carcinogenesis.
The retinoblastoma tumor suppressor is a key regulator of this step in the cell cycle.
Results: Here we use a structure–function approach to evaluate the contributions of multiple protein interaction
surfaces on pRB towards cell cycle regulation. SAOS2 cell cycle arrest assays showed that disruption of three separate
binding surfaces were necessary to inhibit pRB-mediated cell cycle control. Surprisingly, mutation of some interaction surfaces had no effect on their own. Rather, they only contributed to cell cycle arrest in the absence of other pRB
dependent arrest functions. Specifically, our data shows that pRB–E2F interactions are competitive with pRB–CDH1
interactions, implying that interchangeable growth arrest functions underlie pRB’s ability to block proliferation. Additionally, disruption of similar cell cycle control mechanisms in genetically modified mutant mice results in ectopic
DNA synthesis in the liver.
Conclusions: Our work demonstrates that pRB utilizes a network of mechanisms to prevent cell cycle entry. This has
important implications for the use of new CDK4/6 inhibitors that aim to activate this proliferative control network.
Keywords: Cell cycle, Tumor suppressor, Structure–function, Retinoblastoma, Systems biology
Background
Uninhibited cellular division is a feature of cancer cells.
As such, pathways that regulate proliferation are typically disrupted in human cancer [1]. At a molecular
level, the cell division cycle is frequently controlled by
decisions made in the G1 phase [2]. Once through this
phase, the cell is committed to DNA replication and ultimately completion of cell division. The retinoblastoma
gene product (pRB) has been shown to be a key regulator of the restriction point that is responsible for controlling S-phase entry [3]. The best known function of pRB
is the repression of E2F transcription factor activity [4].
RB performs this function by directly binding the transactivation domain of E2Fs, preventing the recruitment of
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transcriptional activators to influence gene transcription
[4]. In addition, pRB can recruit chromatin regulating
enzymes, such as histone deacetylases, to assist in transcriptional repression [5]. This blocks gene expression
that is necessary for DNA synthesis and cell cycle entry
[2]. In the presence of mitogens cyclin dependent kinases
phosphorylate pRB, changing its conformation and
releasing E2Fs [6]. Free E2Fs are then able to stimulate
transcription and S-phase progression. While this model
describes cell cycle entry quite accurately, the role for the
same molecular interactions between pRB and E2Fs in
cell cycle exit is less clear as pRB dependent arrest can
occur much faster than E2F repression [7].
The minimal interaction domain that mediates stable
E2F binding to pRB is the large pocket, and this fragment is also the minimal growth suppressing domain [8,
9]. The large pocket is composed of three regions called
A, B, and C [3]. The A and B domains of pRB form the
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pocket in which the transactivation domain of E2Fs
bind [10, 11]. In addition, pRB interacts with a number
of chromatin regulators, including HDAC containing
complexes, through a well conserved interaction site on
the B box of pRB known as the LxCxE binding cleft [5].
This binding site is well defined for its ability to contact
the LxCxE motif in viral oncoproteins [12]. Simultaneous interactions between E2Fs, pRB, and chromatin
regulators through LxCxE interactions form the basis
of active transcriptional repression through E2Fs. The
C-terminus of pRB is largely unstructured and serves as
a contact point for numerous protein interactions [3, 13].
It is required for stable interaction with E2F-DP dimers
[14], as well as a unique interaction with the marked box
domain of E2F1 [15]. Analysis of the large pocket of pRB
has contributed to our knowledge of E2Fs in cell cycle
control. However, there is little to reconcile how multiple competing protein interactions through this domain
contribute to pRB’s overall influence on cell proliferation.
Genetic ablation of RB causes defects in cell proliferation control in tissues and in primary cell culture experiments [16, 17]. However, early studies of pRB-mediated
cell cycle regulation exploited the RB null SAOS2 osteosarcoma cell line [8, 9, 18]. RB expression in these cells
leads to a robust accumulation of 2 N DNA content, indicating a G1 arrest [19]. These studies looked at a variety
of mutant versions of pRB in which strong cancer derived
mutations were functionless, but low penetrance RB
mutations retained the ability to at least partially restrict
cell cycle entry [8, 9, 20, 21]. Surprisingly, the low penetrance mutation R661W was defective for E2F binding,
but retained the ability to inhibit cell cycle entry [20–22].
More recently, a number of studies have shown that the
R661W mutant can regulate cyclin dependent kinase
activity through p27, independent of E2F transcriptional
control [7, 23]. Importantly, these studies established that
the LxCxE binding cleft and C domains within the large
pocket also mediate interactions with the anaphase promoting complex and Skp2 to stabilize p27 expression [7,
24]. Surprisingly, a unified model of how E2F dependent
and independent proliferative control mechanisms interact has yet to emerge.
To understand the importance of different protein
interaction points in the RB large pocket, targeted mutations to disrupt the LxCxE binding cleft [25–28], the
canonical E2F binding site [29, 30], and pRB’s unique
interaction with E2F1 in the C-terminus [31, 32], have
been generated in mice. Analysis of proliferation in cells
and tissues from these mutant animals suggests that individual protein interactions play context specific roles. For
example, LxCxE binding cleft mutant mice (called Rb1L,
or Rb1NF) are viable with hyper proliferation largely limited to mammary ductal epithelium, that is likely due
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to unresponsiveness to growth inhibitory signals from
TGF-β [33]. Importantly, these mice are not spontaneously cancer prone [27, 34], and they are capable of
blocking E2F transcription under a number of physiological circumstances [35]. However, repression of E2F
targets is diminished following DNA damage, and the
ability of these cells to enter senescence is compromised
[35, 36]. Furthermore, mutagen treatment induces cancer in these mice under conditions where E2F repression
fails [26]. Disruption of pRB’s unique E2F1 interaction in
mice (called Rb1S) shows no detectable change in proliferative control in tissues or isolated cells [32]. Lastly,
mutational disruption of pRB–E2F interactions in Rb1G/G
mice results in cells with accelerated entry into the cell
cycle, but normal cell cycle exit [29, 30]. Remarkably, this
mutation does not predispose mice to cancer [29], however, disruption of this interaction in combination with
p27 deficiency deregulates cell cycle arrest functions
and these mice are highly cancer prone [30]. This result
is also provocative because the cell cycle arrest defects in
Rb1G/G; p27 deficient compound mutants aren’t found in
either single mutant strain alone. These data suggest that
pRB dependent cell cycle arrest may depend on a complex network of proliferative control signals such that loss
of individual functions have limited effect on their own.
This concept is underscored by the fact that no targeted
knock in strain recapitulates the complete proliferative
control and cancer susceptibility phenotypes of Rb1−/−
mice. In this manuscript, we aimed to eliminate individual binding surfaces in the pRB large pocket to determine
the extent that each contributes to cell cycle control
alone and in combinations using SAOS2 arrest as a read
out. Here, we demonstrate that multiple individual binding surfaces in the large pocket contribute to pRB-mediated cell cycle control in cell culture, and provide proof
of principle that this network functions endogenously to
regulate DNA replication in the liver.

Methods
GST pulldowns and western blotting

C33A cells were transfected with either HA-E2F1-3
(along with DP1), myc tagged CDH1 or pRB expression
plasmids under the control of CMV promoters using
standard calcium phosphate precipitation techniques.
40 h after transfection cells were washed and collected in
GSE buffer (20 mM Tris, pH 7.5, 420 mM NaCl, 1.5 mM
MgCl2, 0.2 mM EDTA, 25% glycerol, 5 µg/mL leupeptin,
5 µg/mL aprotinin, 0.1 mM Na3VO4, 0.5 mM NaF, and
1 mM DTT) and frozen at −80 °C. Cell extracts were
centrifuged and the supernatant was diluted twofold
in low salt GSE (20 mM Tris, pH 7.5, 1.5 mM MgCl2,
0.2 mM EDTA, 25 mM DTT, 0.1% NP-40) and combined
with glutathione beads and recombinant fusion proteins.
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GST-RB large pocket (amino acids 379–928) and GSTHPV-E7 recombinant proteins were expressed and purified as previously described [29]. Beads were then washed
twice with low salt GSE, boiled in SDS-sample buffer,
resolved by SDS-PAGE, and western blotted. HA-tagged
proteins were detected using anti-HA 3F10 (Roche),
myc-tagged CDH1 was detected using monoclonal antibody 9E11, and pRB was detected with G3-245 (BD Pharmagen). In order to test pRB stability, cells transfected
with CMV expressed pRB were treated with 100 µg/mL
cycloheximide for 24 h. Extracts were prepared in GSE
buffer every 3 h up to 15 h. Extracts were spun down and
western blotted for pRB.
SAOS2 cell cycle arrest assays

SAOS2 cells were transfected and harvested as previously described [37]. Briefly 106 cells were plated in 6 cm
dishes and transfected with 0.15 µg of CMV-pRB, 1 µg of
CMV-CD20 and 3.85 µg of CMV-β-gal, or 1 µg of CMVCD20 and 4 µg of CMV-β-gal as a negative control, using
X-tremeGENE transfection reagent (Roche). Cells were
re-plated onto 10 cm dishes 24 h after transfection, and
harvested 48 h later. Cells were then stained with a fluorescein conjugated anti-CD20 antibody to mark successfully transfected cells, as well as with propidium iodide
(PI) to determine their DNA content. Flow cytometry
was then performed to identify the percentage of CD20
positive cells with 2 N DNA content as a measure of G1.
In experiments expressing cell cycle arrest as percent
change in G1, arrest data was scaled using CMV-pRB
and CMV-β-gal as standards for maximal increase and
unchanged G1 content allowing comparisons between
different batches of experiments.
Animal housing, dissection and histology

All animals were housed and handled as approved by the
Canadian Council on Animal Care. Mice were sacrificed
at 8 weeks of age, dissected, and livers were processed
for downstream applications. For histology, livers were
fixed in formalin for 72 h followed by 72 h in PBS before
being stored in 70% ethanol. Livers were then embedded
in paraffin and five micron sections were cut and stained
with Hematoxylin and Eosin. Images were captured on a
Zeiss Axioskop 40 microscope and Spot Flex camera, and
nuclear area in the livers was calculated using EyeImage
software (Empix Imaging, Mississauga, Ontario, Canada).
Ploidy analysis of adult livers

A small piece of frozen liver was added to buffer A
(25 mM Tris pH 7.5, 50 mM KCl, 2 mM MgCl2, 1 mM
EDTA, 1 mM PMSF). Tissue was ground on ice with
a mechanical tissue grinder. Tissue was then homogenized using a 1 mL dounce homogenizer and tight
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pestle. Nuclei were centrifuged at 12,000×g, then washed
in buffer A and centrifuged. The pellet was then resuspended in Propidium Iodide solution (0.5 mg/mL PI,
0.1% NP-40, 0.1% sodium citrate, 40 µg/mL RNase A in
PBS). Samples were then analyzed by flow cytometry
using standard methods to quantitate DNA content.
RNA isolation and E2F target gene quantification

RNA from livers was isolated using an RNeasy fibrous
tissue kit (Invitrogen). Expression levels of the E2F target
genes, Pcna, Ccne1 (cyclin E1), Ccna2 (cyclin A2), Tyms
(thymidylate synthase), Mcm3, and Rbl1 (p107), were
determined using the Quantigene Plex 2.0 reagent system from Affymetrix (Santa Clara, CA) and a BioPlex200
multiplex analysis system as previously reported [38].
Expression levels were normalized to the expression of
β-actin.
BrdU staining of tissue sections

To analyze DNA replication, mice were injected with
200 μL of 16 µg/mL BrdU (Sigma) in their peritoneal
cavity 2 h before sacrifice. Livers were then isolated,
fixed in formalin, embedded, and sectioned according
as above. Sections were deparaffinized and rehydrated
using a series of xylene and ethanol washes. The sections were brought to a boil in sodium citrate buffer and
then maintained at 95 °C for 10 min. The cooled sections were rinsed in water three times for 5 min, and
then rinsed in PBS for 5 min. The sections were blocked
in phosphate buffered saline (PBS) supplemented with
2.5% horse serum and 0.3% Triton X-100 for 1 h. The
sections were then incubated with anti-BrdU antibodies
(BD-Biosciences) in blocking buffer overnight at 4 °C and
rinsed in PBS three times for 5 min each time. The slides
were incubated with horse anti-mouse immunoglobulin
G-fluorescein isothiocyanate (Vector) for 1 h and rinsed
in PBS. The slides were then mounted with Vectashield
plus DAPI (Vector). Fluorescent images were captured
on a Zeiss Axioskop40 microscope and Spot Flex camera
and colored using EyeImage software (Empix Imaging,
Mississauga, Ontario, Canada), or a similar system.

Results
A cell culture assay demonstrates molecular redundancy
of RB functions in proliferative control

Tumor suppression by the retinoblastoma protein has
typically been associated with its ability to block cell
cycle progression and repress E2F transcription factors
[4]. However, defective E2F binding by pRB has been
shown to have modest effects on proliferative control in
SAOS2 cell culture experiments [15, 20–22], and gene
targeted mouse models [29, 30]. In an attempt to describe
the molecular interactions necessary for pRB-mediated
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cell cycle arrest we investigated forms of pRB that were
individually mutated at each of three distinct binding
surfaces in the large pocket; the general E2F binding site
(RBG), the E2F1 specific site (RBS), and the LxCxE binding cleft (using either the RBL or RBC mutations). Figure 1a diagrams pRB protein interactions and shows the
relevant regions in each open reading frame that participate. Amino acid substitutions that are demonstrated to
disrupt these contacts are shown in Fig. 1b [24, 37, 39,
40], along with single letter nomenclature for each allele

Fig. 1 Interaction domains located in the large pocket of pRB and
substitutions used in this study. a Linear diagrams of open reading
frames for the indicated proteins highlighting the regions that mediate interactions with pRB. pRB can bind E2F1-4 through the transactivation domain in the C-terminus of E2Fs known as the ‘general’
interaction. Alternatively, pRB can also bind the marked box domain
of E2F1 through its C-terminal domain, termed the RB-E2F1 ‘specific’
interaction. b Locations of point mutations within the pRB open
reading frame used in this study. RBG refers to mutations that disrupt
the E2F general interaction, RBS is a mutation that disrupts the E2F1
specific interaction. RBC and RBL both disrupt interactions through
the LxCxE binding cleft. All codon numbers correspond to the
human sequence. The large pocket domain is amino acids 379–928.
c Diagram depicting the cell cycle control mechanisms that can be
influenced by the 3 pRB binding surface mutations used in this study

Page 4 of 11

(e.g. RBG). Lastly, the types of interactions between pRB
and E2Fs, or LxCxE motif proteins, are illustrated with
the alleles that disrupt them individually shown on the
right, and the intended effect of a combined mutant allele
on the left (Fig. 1c).
GST-tagged versions of the pRB large pocket (GSTRBLP, pRB amino acids 379–928) containing the 3 mutations described above, as well as the triple mutant, were
produced in bacteria. GST pulldowns were performed
to test interaction defects predicted to occur in these
mutants (Fig. 2a). RB deficient C33A lysates derived from
transfections with the indicated E2Fs, or CDH1 were produced and used in pulldown experiments. As expected
the RBG mutation disrupts binding of the activator E2Fs,
E2F2 and E2F3. RBL disrupts the LxCxE binding cleft and
is defective for binding the anaphase promoting complex
targeting subunit CDH1. Finally, since E2F1 is capable of
associating with pRB through two qualitatively different
interactions, the general site and the specific site, binding is only lost following mutation of both sites in the
triple mutant RBGSL. Full length pRB constructs containing these mutations were then transfected into SAOS2
cells to determine their effectiveness in causing a G1 cell
cycle accumulation. As previously shown, expression of
wild-type pRB in SAOS2 cells lead to a build up of cells
in G1 as determined by propidium iodide staining and
flow cytometry (Fig. 2b) [19]. Expression of the mutant
constructs of pRB had various levels of effectiveness for
inducing a G1 cell cycle arrest (Fig. 2b). Notably, the RBS
mutation showed a similar ability to block proliferation
as wild-type RB (Fig. 2b). By contrast, disruption of the
general binding pocket in the RBG mutant, or disruption
of the LxCxE binding cleft (RBL) resulted in a significant,
but partial decrease in the percentage of cells in the G1
phase of the cell cycle (Fig. 2b). Importantly, no individual mutation is able to completely disrupt RB function. However, when all three mutations were combined
into one pRB molecule (RBGSL), the ability of pRBGSL to
induce a G1 arrest was not statistically different from
that of the β-Gal negative control (Fig. 2b). As disruption of the various interactions lead to an inability of
pRB to bind to any of its LxCxE or E2F interactors, we
next aimed to confirm that combination mutations led
to disruption of these binding surfaces, as opposed to
simply disrupting pRB structure or stability. To address
this possibility, we used the RBC mutation that retains
the ability to associate with HPV-E7, but has previously
been shown to be defective for its interaction with CDH1
[24]. Figure 2c demonstrates that both the RBC, and an
RBGSC combination were able to maintain RB-E7 interaction, suggesting this mutant combination retains it structure. Furthermore, the stability of the RBGSC mutation
was determined by expressing both RBWT and RBGSC in
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Fig. 2 Multiple point mutations are needed to overcome RB mediated cell cycle arrest. a GST-tagged RB large pocket proteins corresponding to
the RBG, RBS, RBL, and RBGSL mutant versions of pRB were produced and purified. These GST-fusions were incubated with C33A extracts transfected
with the indicated expression constructs. Bound proteins were isolated by precipitation and identified by western blotting. b Constructs containing full-length RB harboring the indicated mutations under the control of a CMV promoter were transfected into SAOS2 cells along with a CD20
reporter. Cells were then stained with propidium iodide and the percentage of cells in G1 were determined by DNA content of CD20 positive cells.
Bars indicate the mean of three separate experiments, and error bars indicate one standard deviation from the mean. Letters indicate groups that are
significantly different from one another (ANOVA, Tukey test, p < 0.05). c Full length CMV-RB constructs were transfected into C33A cells and extracts
were incubated with recombinant HPV-E7. Bound proteins were isolated by precipitation and western blotted to detect pRB. d Full length RBWT and
RBGSC were transfected into C33A cells prior to cycloheximide treatment (CHX). Extracts were prepared over a 15 h time course and stability was
monitored by Western blotting. e Constructs containing full-length RB harboring the various mutations, or combinations of mutations, under the
control of a CMV promoter were transfected into SAOS2 cells along with a CD20 reporter. Cells were then stained with propidium iodide and the
percentage of cells in G1 were determined by DNA content of CD20 positive cells. Bars indicate the mean of three separate experiments, and error
bars indicate one standard deviation from the mean. f Transfections and cell cycle analysis were performed as in b and e, except the increase in G1
cells is shown as Change in % G1 (relative to β-Gal control). Letters indicate groups that are significantly different from one another (ANOVA, Tukey
test, p < 0.05)
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C33A cells. Cells were then treated with cycloheximide
and protein was isolated over a period of 15 h. Western
blots confirmed that RBWT and RBGSC have equal stability, further suggesting that these substitutions do not
result in the misfolding and hence pleiotropic loss of pRB
function (Fig. 2d). Finally, SAOS2 cell cycle arrest assays
were performed using the RBC mutant alone or in double and triple combinations (RBGC or RBGSC). As with the
RBGSL mutant, the triple mutant combination RBGSC was
unable to increase the proportion of G1 cells beyond that
of β-Gal controls (Fig. 2e). In addition, SAOS2 cell cycle
arrest following transfection with the RBGC and RBGS
double mutants diminished the ability to induce a G1
cell cycle arrest beyond any single mutant, but was less
detrimental than the RBGSC combination (Fig. 2f ). These
results demonstrate that pRB’s activity in this arrest
assay can be defined through loss of individual protein
interactions.
The combination of RBG and RBL mutations in RBGSL
is more severe than either alone (Fig. 2b). It is difficult
to envision LxCxE interaction defects enhancing loss of
function of pRB-E2F binding defects through transcriptional control since the RBG mutation already disrupts
recruitment to E2F promoters [29, 30]. For this reason, we investigated non-E2F dependent mechanisms
that could be lost because of the RBL mutation such as
binding to CDH1. In order to investigate how E2F and
CDH1 dependent arrest mechanisms may relate to one
another, we tested pRB’s ability to interact with each
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simultaneously. For this experiment we mixed C33A
extracts containing myc-tagged CDH1 with increasing amounts of HA-E2F3/DP1 extracts and tested their
ability to bind to GST-RBLP in pulldown experiments
(Fig. 3). This experiment reveals that increasing quantities of HA-E2F3/DP1 prevent myc-CDH1 from binding to GST-RBLP (Fig. 3, left side). Disruption of E2F3
binding to pRB using a GST-RBLPG mutant prevents
competition with myc-CDH1 for binding to pRB. This
experiment suggests that pRB is unable to engage E2F3
and CDH1 dependent functions simultaneously, suggesting that these functions are interchangeable. This mirrors
findings from recent in vivo approaches to pRB dependent cell cycle control [30], and this will be explored further in the discussion.
A compound mutant mouse model demonstrates
molecular redundancy in RB control of DNA replication

Mutation of all three binding surfaces in the RB large
pocket was required to maximally impair RB mediated
cell cycle control (Fig. 2b, e). This finding, combined with
the fact that individual mutations for each of these binding sites in gene targeted mice did not phenocopy the
Rb1−/− proliferative control defects in primary cell culture, suggests that the function of pRB in cell cycle control may be composed of several distinct mechanisms
[28, 29, 32]. To approximate the dysfunction of the RBGSL
mutation in vivo as diagrammed in Fig. 1c, we combined
our previously published Rb1G/G animals that disrupts

Fig. 3 Competition between E2Fs and CDH1 for pRB binding. Purified GST-RBLP or an -RBLPG mutant was incubated with constant levels of
myc-CDH1, and increasing quantities of HA-tagged E2F3/DP1 from transfected lysates. GST-pulldowns were performed and associated levels of
myc-CDH1 and HA-E2F3/DP1 were determined by western blotting. Western blots using anti-pRB antibodies show the levels of GST-RBLP proteins
precipitated in each experiment
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RB-E2F interactions with p27 null mice (Cdkn1b−/−)
to eliminate its influence on cell cycle control [30]. In
addition, we crossed these mice into an E2F1 null background to eliminate any effect on cell cycle regulation
by the pRB-E2F1 specific interaction. This combination
of mutations Rb1G/G; Cdkn1b−/−; E2f1−/−, represents
one potential scenario of the effects of the RBGSL mutation in vivo on cell cycle control. Interestingly, Rb1G/G;
Cdkn1b−/−; E2f1−/− (triple mutant) animals are viable
and occur at normal Mendelian ratios (Table 1).
Since triple mutant mice did not phenocopy the embryonic lethality seen in Rb1−/− animals we next sought to
determine if any tissues display loss of cell cycle control
[41]. Previously, Mayhew et al. showed that tissue specific
knockout of pRB in the murine liver resulted in the up
regulation of E2F target genes and ectopic DNA replication, endoreduplication, and accumulation of nuclei with
elevated ploidy [42]. Since hepatocytes often endoreduplicate it is possible to detect the accumulation of misregulated DNA replication over time [35]. We therefore,
aimed to analyze aspects of cell cycle control in the livers of Rb1G/G; Cdkn1b−/−; E2f1−/− animals to determine
if these mutations were capable of disrupting pRB control
of DNA replication. H&E staining of livers revealed that
hepatocyte triple mutant adult livers had enlarged nuclei
that on average were three times larger that wild-type
and Rb1G/G; Cdkn1b−/− double mutant animals as well
as twice as large as Rb1G/G and Rb1G/G; E2f1−/− nuclei
(Fig. 4a, b). We also quantitated the density of hepatocytes per microscopic field of view and did not see significant differences between genotypes (Fig. 3c). Since
nuclear area in liver histology correlates with DNA content [43], this suggested elevated levels of endoreduplication in Rb1G/G; Cdkn1b−/−; E2f1−/− triple mutant livers.
Table 1 Frequency of compound mutant mice
E2f1−/−; Rb1G/+; Cdkn1b+/− × E2f1−/−; Rb1G/+; Cdkn1b+/−
Genotype
−/−

E2f1

+/+

; Rb1

+/+

; Cdkn1b

P14
8 (13)

E2f1−/−; Rb1+/+; Cdkn1b+/−

29 (26)

E2f1−/−; Rb1+/+; Cdkn1b−/−

12 (13)

E2f1−/−; Rb1G/+; Cdkn1b+/+

29 (26)

E2f1−/−; Rb1G/+; Cdkn1b+/−

64 (52)

E2f1−/−; Rb1G/+; Cdkn1b−/−

9a (26)

E2f1−/−; Rb1G/G; Cdkn1b+/+

12 (13)

E2f1−/−; Rb1G/G; Cdkn1b+/−

35 (26)

E2f1−/−; Rb1G/G; Cdkn1b−/−

10 (13)

Total

208

The indicated genotypes of mice were crossed and all resulting progeny were
genotyped. The number of live animals obtained at 2 weeks of age is indicated
for each genotype and the expected number based on Mendelian inheritance is
indicated in brackets
a

Indicates significance as determined by Chi squared test

To test whether our triple mutant had elevated ploidy in
their hepatocytes, nuclei were extracted from livers of
Rb1+/+, Rb1G/G, and Rb1G/G; Cdkn1b−/−; E2f1−/− mice,
stained with propidium iodine, and analyzed by flow
cytometry for DNA content. Consistent with previous
results we found that Rb1+/+ livers at 8 weeks of age display very low levels of 8 N DNA content, however triple
mutant livers displayed a significant increase in the level
of 8 N DNA at this time point (Fig. 4c), that is similar to
what is reported when Rb1 is conditionally deleted in this
organ [42]. This increase in nuclear size and subsequent
DNA content indicates that triple mutant livers undergo
endoreduplication. While this is a normal phenotype for
liver cells over time, this suggests that the loss of these
three regulatory elements controlled by pRB results in
earlier endoreduplication, potentially due to a loss of cell
cycle control.
We next wanted to determine the effect of our combined mutations on the regulation of pRB functions
related to cell cycle control. To accomplish this, RNA
was isolated from adult livers to analyze the expression
of E2F target gene transcription. Consistent with our
previous findings, E2F target gene expression in Rb1G/G
animals is higher than wild-type levels [29]. Interestingly, triple mutant livers show high expression of some
of these target genes (Fig. 4e). However, in some cases,
E2F target gene expression is unchanged from wild type
and this will be discussed later. To directly measure proliferation in livers, 8-week-old animals were injected with
BrdU to label nuclei with actively replicating DNA. Livers
were dissected, sectioned and stained for BrdU incorporation. This analysis showed that while both Rb1G/G and
Rb1G/G; Cdkn1b−/−; E2f1−/− livers display increases in
the expression of E2F target genes only triple mutant livers displayed increased BrdU incorporation (Fig. 4e, f ).
Taken together with the increased nuclear area and 8 N
DNA content in triple mutant livers, these results suggest that by mutating the general binding site of pRB, and
eliminating both p27 and E2F1, we have recapitulated
the DNA replication defects associated with conditional
deletion of Rb1 in adult livers. These in vivo results also
mirror the effects seen in the SAOS2 arrest assays that
suggest that no individual protein interaction with pRB
accounts for its activity in cell cycle control. Instead,
these data indicate that pRB likely sits in the center of a
network of regulators that control DNA replication and
cell division.

Discussion
In this manuscript we aimed to further the understanding of pRB-mediated cell cycle control by disrupting pRB-binding interactions in the large pocket to
quantitatively account for its arrest mechanisms. This
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Fig. 4 Ectopic DNA-replication in Rb1G/G; Cdkn1b−/−; E2f1−/− compound mutant mice. a H&E staining of liver sections from 8-week old wild type,
Rb1G/G, double mutant Rb1G/G; Cdkn1b−/−, and Rb1G/G; E2f1−/− mice, as well as Rb1G/G; Cdkn1b−/−; E2f1−/− triple mutant animals. The scale bars
represent 20 μm. b Nuclear size from the images in a was determined and the mean size is indicated. Measurements were made from at least 50
nuclei, a, b, c represents statistically different groups as determined by ANOVA followed by Tukey’s test (p < 0.05). c Total number of hepatocytes per
20X field of view was averaged from the indicated genotypes. No statistical differences were observed by AVONA followed by Tukey’s test (p < 0.05)
d Nuclei were extracted from livers, stained with propidium iodide, and analyzed for DNA content by flow cytometry. e The relative expression level
of six E2F cell cycle target genes from wild type, Rb1G/G, and Rb1G/G; Cdkn1b−/−; E2f1−/− was determined from RNA extracted from 8-week-old livers.
f 8-week-old mice were pulse labeled with BrdU 2 h prior to sacrifice and livers were sectioned and stained for BrdU. The percentage of BrdU positive nuclei was determined. At least 500 nuclei were counted per mouse. All bar graphs represent at least 3 individual experiments, and error bars
indicate one standard deviation from the mean. An asterisk represents a statistically significant difference from the wild type control (t test, P < 0.05)
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structure–function analysis demonstrated that in order
to disrupt the vast majority of pRB’s cell cycle arrest activity, three different binding surfaces needed to be altered.
Surprisingly, no single interaction site was indispensible
and disruption of some interaction sites had little effect
on their own. We used a genetic cross to cripple these
three aspects of pRB function endogenously and the
combination caused ectopic DNA replication in the liver.
This suggests that pRB may interchangeably use different
protein interactions to influence cell cycle advancement.
Insights and caveats of our study are discussed below.
It is difficult to predict the proliferative control defects
of an Rb1 deficient mouse beyond neonatal lethality
due to muscle atrophy [44]. Interestingly, chimeric mice
composed of a mixture of wild type and Rb1−/− cells are
viable and demonstrate normal tissue cellularity, even in
organs where Rb1−/− cells contribute extensively [17].
This study reveals that livers containing Rb1−/− hepatocytes display random, large nuclei, similar to our findings
in triple mutant livers [17]. In addition, conditional ablation of Rb1 in the livers of adult mice is reported to cause
unscheduled DNA replication [42]. The increase in DNA
copy number and BrdU incorporation was indicative of
a loss of regulation of DNA synthesis [42]. In an effort to
model the effects of the RBGSL mutant in vivo, we combined Rb1G/G animals with p27 and E2F1 deficiency to
produce triple mutant animals (Rb1G/G; Cdkn1b−/−;
E2f1−/−). This combination of mutations lead to a very
similar DNA replication phenotype in the liver as complete Rb1 deletion. While this is a similar phenotype as
conditional deletion of Rb1, by no means does our study
elucidate all that pRB pr E2Fs do to block the cell cycle
in this or other tissues. We anticipate that viability of
triple mutant mice suggests additional pRB dependent
cell cycle arrest mechanisms likely remain functional in
these animals. Another important consideration in our
efforts to model the RBGSL mutant in vivo is that deleting
Cdkn1b and E2f1 is not the equivalent to disrupting the
binding sites on pRB that regulate them, as these interaction sites may have additional regulatory effects beyond
the downstream targets we have chosen. In addition,
loss of E2F1 could diminish cell proliferation even when
entry into S-phase is deregulated and this could further
complicate the interpretation of our analysis of triple
mutant livers. Importantly, others have demonstrated
that the choice between proliferation and endoreduplication in hepatocytes is determined by opposing effects
of activator E2Fs (such as E2F1) and the E2F7 and E2F8
repressors [45, 46]. It is difficult to predict how the triple
mutant combination used here would affect the regulation of this network of genes to cause a switch to endoreduplication. Future experiments using Rb1 gene targeted
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mice carrying a combination of G, S, or L mutations in a
single allele will help resolve some of these complexities.
We observed that some individual mutations contributed modestly to proliferative control alone, and more
strongly when in combination with other substitutions.
We suggest that this may be due in part to the competition between different cell cycle control mechanisms for
access to pRB. For example, we demonstrate that E2F3
and CDH1 can compete for the opportunity to interact
with pRB, and this is consistent with previous reports of
E2F1 and CDH1 competing for pRB [47]. We suggest that
CDH1 interactions with pRB are fundamentally different than other pRB interactors that contact the LXCXE
binding site simultaneously with E2Fs [3]. Another way
to consider redundancy of function through endogenous
pRB is a gene targeted mouse model bearing an R654W
mutation (the murine equivalent of the low penetrance
human mutation R661W). This mutation not only disrupts E2F binding, it also compromised interactions at
the LXCXE cleft [20], potentially illustrating the effects
of multiple mutations in a single pRB molecule akin to
RBGC in our studies. Fibroblast cells from these mice possess many features of deregulated proliferation seen in
Rb1−/− cells and this mutation is lethal during embryogenesis [48]. However, some aspects of pRB’s role in
differentiation and its ability to respond to senescence
inducing stimuli and resistance to tumor formation are
retained [48, 49], suggesting that simultaneous deficiency
by pRB for multiple interactions can reveal a more dramatic phenotype than loss of single interactions. This
conclusion is further supported by deregulated cell cycle
control and cancer incidence in Rb1G/G; Cdkn1b−/− mice
[30], suggesting loss of multiple pRB dependent proliferative control pathways can be dramatically different than
loss of a single pathway.
Consistent with multiple interactions needing to be
compromised to abrogate cell cycle arrest by pRB, we
also note that some mutations tested in this study, such
as the M851A, V852A changes (RBS), have no effect on
proliferative control in the SAOS2 assay on their own.
We suggest that it may represent a latent proliferative
control mechanism used by pRB, and there may be others. A long standing puzzle in the RB field has been the
existence of proliferative control mechanisms that are
mediated by the N-terminus of pRB, outside of the original growth suppressing large pocket domain [50–52].
Recent work has suggested that the N-terminus also
plays a role in regulating DNA replication [52]. This may
explain the phenotypic difference in proliferative control between Rb1−/− animals and that of triple mutant
Rb1G/G; Cdkn1b−/−; E2f1−/− animals as the N-terminus
is unaffected by our three mutations. There may also
be redundancy between N-terminal and large pocket
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growth arrest mechanisms. Provocatively, there are also
low penetrance mutations in human RB1 that target
this region of pRB; further suggesting the N-terminus
contributes to pRB’s proliferative control and tumor
suppressor functions [53]. We think that interchangeability of different pRB functions in proliferative control
best explains our data and also encompasses additional
work in the field that has previously been difficult to
reconcile.
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Conclusions
RB dependent proliferative control is functionally inactivated in the vast majority of cancers, this study furthers
our understanding of the importance of the various interaction surfaces of pRB and their roles in cell cycle control. In addition, CDK4/6 inhibitors have recently been
developed to reactivate the RB-pathway in cancer [54–
56]. Understanding the molecular interactions made by
pRB and how they influence cell cycle control and tumor
suppression is crucial to the proper implementation of
these drugs. We expect that the mutational status of both
pRB, as well as its regulation of p27 and E2Fs, will play a
critical role in the effectiveness of these drugs. We suggest that patients whose tumor cells have pRB activatable
p27 will benefit most from CDK4/6 inhibitors.
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